HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
BIOBOARD - INDIA
Biocon receives marketing authorization for novel biologic itolizumab for psoriasis
Biocon, Asia's premier biotechnology company received marketing authorization from the Drugs Controller General of India (DCGI) for its novel biologic itolizumab, anti-CD6 molecule, for the treatment of chronic plaque psoriasis.

Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second novel biologic developed by Biocon at Asia's largest biotech hub in Bangalore.

This approval paves the way for the launch of Biocon's Alzumab TM in India, later during 2013. Alzumab TM is a differentiated biologic drug with a superior safety profile compared to other approved biologic therapies given its very low opportunistic infection rates. A novel biologic indicated for the treatment of Moderate-to-Severe Psoriasis, Alzumab TM will be marketed by Biocon's Immunotherapy Division. Alzumab TM, will be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.

Commenting on this development Ms. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, "We are very excited to receive this marketing authorization for Itolizumab from DCGI which will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India. This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like rheumatoid arthritis, multiple sclerosis and vitiligo. We also intend to file a US IND shortly to enable us to embark on a global clinical development plan. This is a defining moment for Biocon as it reaches a significant milestone in its mission of delivering affordable innovation to patients worldwide."

Alzumab (TM) is expected to provide a safe and effective treatment option for psoriasis, a socially debilitating disease affecting 2-3 % of Indian population. The global psoriasis market size is estimated to cross $8 billion by 2016.

Itolizumab has shown promising preclinical and clinical efficacy in other auto immune diseases like rheumatoid arthritis and multiple sclerosis. The company aims to file a US IND in 2013 to facilitate global clinical trials in psoriasis, rheumatoid arthritis and other indications as a subcutaneous formulation. Biocon plans to develop this molecule with a global partner for various markets across the world.

Click here for the complete issue.

NEWS CRUNCH  
news Medical technology experts to address the impact of innovation in shaping patient outcomes across Asia Pacific
news China biotech's 'coming out party' masks long road ahead
news SingHealth, Duke NUS and GSK to conduct large-scale big data study on asthma and COPD in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy